Amylyx Pharmaceuticals (AMLX) said Friday it priced an underwritten offering of about 17.1 million common shares at $3.50 per share.
The company also said it gave the underwriter a 30-day option to buy up to an additional 2.6 million shares at the offering price.
Gross proceeds are expected to be about $60 million, excluding any exercise of the underwriter's overallotment option, the company said. The net proceeds from the offering, which is expected to close on or about Jan. 13, are expected to be used for working capital and for general corporate purposes and to help advance preparations for commercialization and pipeline programs.
Shares of Amylyx were down 3.2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.